AbCellera Biologics Hits Day High with 12.47% Surge in Stock Price

AbCellera Biologics, Inc. has experienced a significant surge in its stock performance, gaining 12.47% on May 21, 2026. The stock reached an intraday high of USD 5.42, marking a notable milestone for the small-cap company in the Pharmaceuticals & Biotechnology sector. Over the past week, AbCellera has outperformed the S&P 500, with a 16.82% increase compared to the index's decline of 0.74%. The company's one-month performance stands at an impressive 28.82%, significantly higher than the S&P 500's 5.4%. Year-to-date, AbCellera has shown a robust gain of 50.29%, while the S&P 500 has risen by 8.77%. Despite these positive short-term trends, the company has faced challenges, reporting negative results for the last ten consecutive quarters. Key financial metrics indicate a return on capital employed (ROCE) of -16.81% and a debt-equity ratio of -39.26%. The stock's performance over the past three years shows a decline of 11.99%, and a substantial drop of 83.95% over the last five years, highlighting the volatility in its long-term trajectory.